Figs Inc vs uniQure N.V. Ordinary Shares — how do they compare? Figs Inc trades at $18.6 (market cap $3.10B), while uniQure N.V. Ordinary Shares trades at $20.71 (market cap $1.45B). The key difference: Figs Inc is far larger — about 2.1× uniQure N.V. Ordinary Shares's market cap, and Figs Inc is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 31 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| FIGS | QURE | |
|---|---|---|
Market Cap | $3.10B | $1.45B |
Volume | 5,758,739 | 3,323,243 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.63 | $70.59 |
52-Week Low | $7.38 | $9.03 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $2.86B | $707.46M |
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $18.00, up 1.35% with strong technical momentum and bullish moving average signals. The company shows accelerating revenue growth, improving margins, and consistent earnings beats, with Q2 2026 revenue surging 28.8% and international sales up 67%. Recent news highlights international expansion momentum and raised 2026 guidance.
The outlook remains positive with analyst consensus pointing to 26% upside potential, though premium valuation metrics require continued execution. Key risks include rich P/E ratio of 54.6 and execution challenges in maintaining growth momentum amid competitive retail landscape.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →